Tom 7, Nr 5 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-11-25

dostęp otwarty

Wyświetlenia strony 3063
Wyświetlenia/pobrania artykułu 281
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Kliniczne prognostyczne i predykcyjne czynniki kwalifikacji do immunoterapii

Magdalena Knetki-Wróblewska1
Onkol Prakt Klin Edu 2021;7(5):301-306.

Streszczenie

Kwalifikacja chorych do immunoterapii opiera się na wskazaniach rejestracyjnych leków z uwzględnieniem zapisów programów lekowych. Obserwacje z codziennej praktyki pozwalają wskazać dodatkowe czynniki rokownicze i predykcyjne w odniesieniu do immunoterapii. Najbardziej istotnymi elementami negatywnie wpływającymi na skuteczność immunoterapii są: gorszy stan sprawności, lokalizacja zmian wtórnych w wątrobie i mózgowiu, znaczne zaawansowanie zmian, nieprawidłowości w badaniach laboratoryjnych i brak korzyści klinicznej z wcześniej prowadzonego leczenia systemowego . Ponadto obserwuje się brak skuteczności immunoterapii wśród chorych z zaburzeniami molekularnymi (w szczególności w genach EGFR, ALK).

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Manrique MA, Martínez JM, González JG, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018; 7(3): 404–415.
  2. Juergens RA, Mariano C, Jolivet J, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2018; 25(6): 384–392.
  3. Almazan M, Perez J, Pozo J, et al. A multicentre observational study of the effectivenes, safety and economic impact of nivolumab on non-small-cell lung cancer. International Journal of clinical Pharmacy. 2019; 41: 272–279.
  4. Schouten RD, Muller M, de Gooijer CJ, et al. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute. Lung Cancer. 2018; 126: 210–216.
  5. Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cel lung cancer. Lung cancer. 2018; 126: 217–223.
  6. Figueiredo A, Almeida MA, Almodovar MT, et al. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). Pulmonology. 2020; 26(1): 10–17.
  7. Ardizzoni A, Azevedo S, Rubio-Viqueira B, et al. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. J Immunother Cancer. 2021; 9(3).
  8. Velcheti V, Chandwani S, Chen X, et al. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy. 2019; 11(10): 889–901.
  9. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986; 4(11): 1604–1614.
  10. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018; 29(4): 959–965.
  11. Grossi F, Genova C, Crinò L, et al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur J Cancer. 2019; 123: 72–80.
  12. Kitadai R, Okuma Y, Hakozaki T, et al. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. J Cancer Res Clin Oncol. 2020; 146(3): 777–785.
  13. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14): 1505–1517.
  14. Wang S, Hu C, Xie F, et al. Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer. Onco Targets Ther. 2020; 13: 667–683.
  15. Crinò L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019; 129: 35–40.
  16. Mansfield AS, Herbst RS, Castro G, et al. Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042. Ann Oncol. 2019; 30: v604–v606.
  17. Garassino MC, Gelibter AJ, Grossi F, et al. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018; 13(8): 1146–1155.
  18. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.
  19. Fujimoto D, Yoshioka H, Kataoka Y, et al. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer. 2018; 119: 14–20.
  20. Lai G, Alvarez J, Yeo J, et al. Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC OA01.06 WCLC2020.
  21. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8): 1321–1328.
  22. Gandara D, Reck M, Moro-Sibilot D, et al. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021; 9(3).
  23. Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2019; 8(6): 1078–1085.
  24. Mezquita L, Auclin E, Ferrara R, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3): 351–357.
  25. Katsurada M, Nagano T, Tachihara M, et al. Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. Anticancer Res. 2019; 39(2): 815–825.
  26. Hakozaki T, Hosomi Y, Kitadai R, et al. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. J Cancer Res Clin Oncol. 2020; 146(11): 2957–2966.